Chimerix Appoints M. Michelle Berrey, MD, MPH as Chief Executive Officer

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed M. Michelle Berrey, MD, MPH to the position of President and Chief Executive Officer. Dr Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests. In addition, Dr Berrey will continue to serve as Chimerix's Chief Medical Officer.

Prior to joining Chimerix as Chief Medical Officer in November 2012, Dr Berrey was Chief Medical Officer at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 2007 until its acquisition by Gilead Sciences, Inc. in January 2012.

"We are grateful for Ken's contributions to Chimerix and his leadership during the company's transition to a publicly traded company. We are now entering a critical stage of the clinical development of brincidofovir. Our goal is to complete the requirements for regulatory approval of brincidofovir as rapidly as possible and we believe Dr Berrey has the qualifications and expertise in abundance to accomplish that objective," said Ernest Mario, PhD, Chairman of the Board of Directors. "I believe Dr Berrey has demonstrated the leadership skills and vision to guide Chimerix through this critical phase in the company's evolution."

"It is a privilege to be asked to lead Chimerix at this point in the company's growth. I am pleased with our clinical development progress to date for brincidofovir and the strength of the scientific underpinnings of our organisation. Our focus remains to advance brincidofovir toward regulatory approval for the prevention of cytomegalovirus infection and other infections caused by DNA viruses," said Dr Berrey. "Chimerix has the potential to bring an important antiviral for prevention and treatment to immunocompromised patients who today have limited or no treatment available."